Daniel ODay - Gilead Sciences Chairman of the Board, CEO

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;padding-top: 25px;;'>GS</div>
GILD -- USA Stock  

Report: 4th of August 2020  

  Chairman
Mr. Daniel ODay is appointed as Chairman of the Board, Chief Executive Officer of the company. Mr. ODay joined Gilead as Chairman and Chief Executive Officer on March 1, 2019. Prior to Gilead, Mr. ODay served as the Chief Executive Officer of Roche Pharmaceuticals. His career at Roche spanned more than three decades, during which he held a number of executive positions in the companys pharmaceutical and diagnostics divisions in North America, Europe and Asia. During his time at Roche, Mr. ODay demonstrated vision and leadership, helping to engineer the acquisitions of Flatiron Health and Foundation Medicine in 2018. He served as a member of Roches Corporationrationrate Executive Committee, as well as on a number of public and private boards, including Genentech, Inc
Age: 54  Chairman Since 2019  MBA    
650 574-3000  www.gilead.com
O?Day holds a bachelor?s degree in biology from Georgetown University and an MBA from Columbia University in New York.

Daniel ODay Latest Insider Activity

Gilead Sciences Management Efficiency

Gilead Sciences has return on total asset (ROA) of 5.36 % which means that it generated profit of $5.36 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 22.29 %, meaning that it created $22.29 on every $100 dollars invested by stockholders. Gilead Sciences management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. The current year Return on Investment is expected to grow to 9.18. The current year Return on Average Assets is expected to grow to 0.14Gilead Sciences Total Assets Per Share are expected to increase significantly based on the last few years of reporting. The past year's Total Assets Per Share were at 48.68. The current year Asset Turnover is expected to grow to 0.43, whereas Current Assets are expected to decline to about 26.3 B. The current year Tax Liabilities is expected to grow to about 6.6 B, whereas Total Liabilities is expected to decline to about 34.3 B.
The company currently holds 24.1 B in liabilities with Debt to Equity (D/E) ratio of 1.09, which is about average as compared to similar companies. Gilead Sciences has a current ratio of 2.98, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Similar Executives

Showing few of many executives

CHAIRMAN Since

Daniel VasellaNovartis AG
N/A
Joaquin DuatoJohnson Johnson
2018
Alex GorskyJohnson Johnson
2012
Leif JohanssonAstrazeneca PLC
2012
Victor RouraGrifols S A
2017
Kenneth FrazierMerck Company
2011
Sandra PetersonJohnson Johnson
2017
Jennifer TaubertJohnson Johnson
2018
Paulus StoffelsJohnson Johnson
2018
Ashley McEvoyJohnson Johnson
2018
Joerg ReinhardtNovartis AG
2013
Alex KrauerNovartis AG
N/A
Geoffrey GuyGW Pharmaceuticals Plc
N/A
Jorge MesquitaJohnson Johnson
2016
John LechleiterEli Lilly And
2016
Giovanni CaforioBristol Myers Squibb
2017
Enrico VanniNovartis AG
2013
Moncef SlaouiGlaxoSmithKline PLC
2014
Ulrich LehnerNovartis AG
2006
James NobleGW Pharmaceuticals Plc
2007
Lamberto AndreottiBristol Myers Squibb
2015

Company Summary

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California. Gilead Sciences operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 11800 people.Gilead Sciences (GILD) is traded on BATS Exchange in USA. It is located in 333 Lakeside Drive, Foster City, CA 94404, United States and employs 11,800 people. Gilead Sciences is listed under Pharmaceutical Products category by Fama And French industry classification.

Gilead Sciences Leadership Team

Kathleen Watson, Executive Vice President - Human Resources
John McHutchison, Executive Vice President - Clinical Research
Andrew Cheng, Executive Vice President - HIV Therapeutics and Development Operations
John Martin, Chairman and CEO
Andrew Dickinson, Executive Vice President - Corporate Development and Strategy
Gayle Wilson, Independent Director
Daniel ODay, Chairman of the Board, CEO
Jacqueline Barton, Director
Brett Pletcher, Executive VP and General Counsel
William Lee, Executive Vice President - Research
John Madigan, Independent Director
Martin Silverstein, Executive Vice President - Strategy
Kevin Lofton, Independent Director
Paul Carter, Executive Vice President - Commercial Operations
Gregg Alton, Executive VP of Corporate and Medical Affairs and Secretary
Diana Brainard, Senior Vice President HIV and Emerging Viral Infections
Carla Hills, Independent Director
John Cogan, Lead Independent Director
John Milligan, Pres and COO
Nicholas Moore, Independent Director
James Meyers, Executive Vice President - Worldwide Commercial Operations
Katie Watson, Executive Vice President of Human Resources
Kelly Kramer, Director
Johanna Mercier, Chief Commercial Officer
Jyoti Mehra, Executive Vice President of Human Resources
Laura Hamill, Executive Vice President - Worldwide Commercial Operations
Robin Washington, CFO and Executive VP
Norbert Bischofberger, Chief Scientific Officer and Executive VP of RandD
Per WoldOlsen, Independent Director
Harish Manwani, Director
Taiyin Yang, Executive Vice President - Pharmaceutical Development and Manufacturing
Kevin Young, COO
Etienne Davignon, Independent Director
Richard Whitley, Independent Director

Stock Performance Indicators

Current Sentiment - GILD

Gilead Sciences Investor Sentiment

Majority of Macroaxis users are currently bullish on Gilead Sciences. What is your judgment towards investing in Gilead Sciences? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Risk vs Return Analysis. Please also try Probability Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page